Compare KLRS & SUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLRS | SUNS |
|---|---|---|
| Founded | 2019 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.0M | 108.7M |
| IPO Year | 2020 | 2024 |
| Metric | KLRS | SUNS |
|---|---|---|
| Price | $4.18 | $7.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $19.00 | $8.75 |
| AVG Volume (30 Days) | ★ 613.5K | 59.8K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 16.17% |
| EPS Growth | ★ 75.70 | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | $165,000.00 | ★ $21,571,434.00 |
| Revenue This Year | N/A | $70.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.87 |
| Revenue Growth | N/A | ★ 102.96 |
| 52 Week Low | $2.14 | $7.34 |
| 52 Week High | $11.88 | $11.78 |
| Indicator | KLRS | SUNS |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 36.87 |
| Support Level | $3.96 | $7.39 |
| Resistance Level | $4.40 | $8.81 |
| Average True Range (ATR) | 0.33 | 0.24 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 69.34 | 5.74 |
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.